Skip to content
About Us
Board of Directors
Leadership
Scientific Advisory Board
Our Values
History
Pipeline
NTCD-M3 for
Clostridioides difficile
Infections
XF-73 Nasal for Post Surgical Infections
XF-73 for Dermal Infections
SPOR-COV™ for COVID-19
XF Research Programs
Target Markets
Clostridioides difficile Infections
Post Surgical Infections
Dermal Infections
COVID-19
Anti-Microbial Resistance
Our Technologies
Biotherapeutics
NTCD-M3
SPOR-COV™
XF Platform
Business Development
News and Media
Media
Events
Investors
AIM Rule 26
Corporate Governance
Share Price Information
Regulatory News
Constitutional Documents
Reports & Presentations
Advisers / Shareholder Contacts
Analyst Coverage
Email Alerts
Careers
Contact
28 February 2023 – Form of Proxy
Posted on
01/03/2023
by
Kirsty Richardson
Form of Proxy
Post navigation
Previous Post
28 February 2023 – Form of Proxy
Next Post
15 March 2023 – Result of Open Offer